Yellow fever vaccine - Biologic Drug Details

Summary for yellow fever vaccine

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for yellow fever vaccine

Mechanism of Action	Osmotic Activity
Physiological Effect	Increased Large Intestinal Motility Inhibition Large Intestine Fluid/Electrolyte Absorption Actively Acquired Immunity
Established Pharmacologic Class	Osmotic Laxative Live Attenuated Yellow Fever Virus Vaccine
Chemical Structure	Vaccines, Attenuated Yellow Fever Vaccine

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for yellow fever vaccine Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for yellow fever vaccine Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for yellow fever vaccine Derived from Patent Text Search

No patents found based on company disclosures

Yellow fever vaccine Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for the Biologic Drug: Yellow Fever Vaccine

Introduction

The yellow fever vaccine market is a critical segment within the global healthcare industry, driven by the need to prevent and control yellow fever, a deadly disease transmitted by mosquitoes. Here, we will delve into the market dynamics, financial projections, and key factors influencing the growth of the yellow fever vaccine market.

Global Market Size and Forecast

As of 2024, the global yellow fever vaccine market size is estimated to be USD 4528.5 million. This market is projected to expand at a compound annual growth rate (CAGR) of 5.50% from 2024 to 2031, reaching USD 6587.5 million by 2031[1].

Regional Market Analysis

North America

North America holds a significant share of the global yellow fever vaccine market, with sales revenue estimated at USD 1811.4 million in 2024. The region is expected to grow at a CAGR of 3.7% from 2024 to 2031. The United States is the largest market within North America, with sales revenue of USD 1429.19 million in 2024 and a CAGR of 3.5% over the forecast period[1].

Europe

Europe accounts for more than 30% of the global revenue, with a market size of USD 1358.55 million in 2024. The European market is expected to grow at a CAGR of 4.0% from 2024 to 2031. Key markets in Europe include the United Kingdom, France, and Germany, each with their own growth rates and market sizes[1].

Asia Pacific

The Asia Pacific region holds around 23% of the global revenue, with a market size of USD 1041.56 million in 2024. This region is expected to grow at a higher CAGR of 7.5% from 2024 to 2031, driven by countries like China, India, and Brazil[1].

Latin America and Middle East & Africa

Latin America accounts for around 5% of the global revenue, with a market size of USD 226.43 million in 2024 and a CAGR of 4.9%. The Middle East and Africa hold a smaller share, around 2% of the global revenue, with a market size of USD 90.57 million in 2024 and a CAGR of 5.2%[1].

Drivers of Market Growth

Increased Awareness and Travel

The rise in international travel to endemic regions and increased awareness of vector-borne diseases are significant drivers of the yellow fever vaccine market. Mandatory vaccination requirements for travelers further boost demand[1][3].

Healthcare Infrastructure Growth

Improving healthcare infrastructure in emerging nations such as Brazil, India, and China is another key factor driving market growth. This infrastructure expansion enables better access to vaccination programs[3].

Public Health Initiatives

Efforts by global health organizations like the World Health Organization (WHO) and UNICEF play a crucial role in driving the market. Long-term agreements with manufacturers and routine vaccination programs contribute to the market's growth[3].

Challenges and Restraints

Supply Constraints

The global supply of yellow fever vaccines is constrained by the limited number of manufacturers with WHO prequalification status. This can lead to shortages, especially during outbreaks or mass immunization campaigns[4].

Dose-Sparing Strategies

To address supply gaps, dose-sparing strategies have been proposed. These strategies involve administering reduced doses of the vaccine, which can potentially increase the number of doses available by up to fivefold. However, additional clinical trials are needed to confirm the safety and efficacy of these reduced doses[4].

Economic Value and Cost-Effectiveness

Cost-Benefit Analysis

Studies have shown that routine yellow fever vaccination is cost-effective. For example, in Colombia, the cost per disability-adjusted life-year (DALY) averted was $19,022 from a payer's perspective and $12,114 from a societal perspective, indicating that vaccination is economically viable[2].

Financial Savings

Dose-sparing strategies could result in significant financial savings. For instance, preventive yellow fever vaccination campaigns using dose-sparing could conserve up to 420 million doses by 2022, saving around $340 million in vaccine purchase costs over a decade[4].

Market Segmentation

The yellow fever vaccine market is segmented based on transmission type, treatment type, application, and other factors. Understanding these segments helps in identifying the most lucrative areas and their expected growth rates and future market opportunities[1].

Competitive Landscape

The market is characterized by a few major players who have WHO prequalification status. The competitive landscape is influenced by long-term agreements between these manufacturers and global health organizations, as well as the introduction of novel delivery methods and dose-sparing strategies[3][4].

Key Takeaways

• The global yellow fever vaccine market is projected to grow at a CAGR of 5.50% from 2024 to 2031.
• Regional markets such as North America, Europe, and Asia Pacific are significant contributors to the global market.
• Drivers include increased awareness, international travel, and improving healthcare infrastructure.
• Supply constraints and the need for dose-sparing strategies are key challenges.
• The market is cost-effective, with significant economic benefits from vaccination programs.

FAQs

What is the current global market size for yellow fever vaccines?

The global yellow fever vaccine market size is estimated to be USD 4528.5 million in 2024[1].

What is the projected CAGR for the yellow fever vaccine market from 2024 to 2031?

The market is expected to grow at a CAGR of 5.50% from 2024 to 2031[1].

Which regions are the largest markets for yellow fever vaccines?

North America and Europe are among the largest markets, with significant contributions from the United States, the United Kingdom, France, and Germany[1].

What are the main drivers of the yellow fever vaccine market?

Increased awareness of vector-borne diseases, rising international travel, and growth of healthcare infrastructure in endemic regions are key drivers[1][3].

How can dose-sparing strategies impact the yellow fever vaccine market?

Dose-sparing strategies can increase the availability of vaccine doses by up to fivefold, helping to address supply gaps and reduce costs[4].

Cited Sources:

1. Cognitive Market Research. Yellow Fever Vaccine Market Report 2024 (Global Edition).
2. PubMed. The Public Health Benefits and Economic Value of Routine Yellow Fever Vaccination in Colombia.
3. Verified Market Research. Yellow Fever Vaccine Market Size & Forecast.
4. PATH. Novel strategies to expand supply of yellow fever vaccine.